Kefah Mokbel: TP53 Mutation Predicts Shorter CDK4/6 Inhibitor Benefit in ER+/HER2− Breast Cancer – Oncodaily
Kefah Mokbel: TP53 Mutation Predicts Shorter CDK4/6 Inhibitor Benefit in ER+/HER2− Breast Cancer Oncodaily
المصدر: Google News — Pakistan / HEALTH
0
مشاهدة





